{
    "organizations": [],
    "uuid": "4df8dcd60eb3638605d77e3d441d82eb0f2d5547",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-basilea-pharmaceutica-fy-operating/brief-basilea-pharmaceutica-fy-operating-loss-at-chf-14-1-million-idUSFWN1QH01L",
    "ord_in_thread": 0,
    "title": "BRIEF-Basilea Pharmaceutica FY Operating Loss At CHF 14.1 million",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 27 (Reuters) - BASILEA PHARMACEUTICA AG:\n* FY ‍54% INCREASE IN TOTAL REVENUE, AMOUNTING TO CHF 101.5 MILLION​\n* FY OPERATING LOSS REDUCED BY 68% TO CHF 14.1 MILLION * ‍CASH POSITION AS OF YEAR-END 2017 INCREASED TO CHF 310.7 MILLION​\n* ‍NET LOSS IN 2017 WAS REDUCED TO CHF 19.4 MILLION (2016: CHF 51.3 MILLION)​\n* OUTLOOK 2018: ANTICIPATES TOTAL REVENUE OF APPROXIMATELY CHF 105-115 MILLION\n* OPERATING LOSS IN 2018 IS ESTIMATED AT APPROXIMATELY CHF 10-20 MILLION Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-02-27T14:23:00.000+02:00",
    "crawled": "2018-02-28T13:00:41.005+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "basilea",
        "pharmaceutica",
        "ag",
        "fy",
        "increase",
        "total",
        "revenue",
        "amounting",
        "chf",
        "fy",
        "operating",
        "loss",
        "reduced",
        "chf",
        "million",
        "position",
        "increased",
        "chf",
        "loss",
        "reduced",
        "chf",
        "million",
        "chf",
        "million",
        "outlook",
        "anticipates",
        "total",
        "revenue",
        "approximately",
        "chf",
        "million",
        "operating",
        "loss",
        "estimated",
        "approximately",
        "chf",
        "million",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}